FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	: 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     YOUNG WILLIAM D					2. Issuer Name and Ticker or Trading Symbol Praxis Precision Medicines, Inc. [ PRAX ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)			(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/12/2023						X Dire	er (give title		10% Ov Other (s below)	· I		
C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person							
(Street) BOSTO	N M	<b>A</b>	02110		1	401.5	4 ( - )	\ <b>T</b>			Para Para		Fori Per	n filed by Mo on	re tha	n One Repo	rting
(City)	(S	tate)	(Zip)	_   Ri	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Inst						ant to a co						
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,			Code (Instr. 5)			Secu Bene Owne	icially d Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	t (A) or Pr		Trans	orted nsaction(s) tr. 3 and 4)			(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any		Code (I	ransaction of Code (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative St (Instr. 3 and			f s g Security	8. Price Derivativ Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.957	06/12/2023		A		28,981		(1)	06	5/12/2033	Common Stock	28,981	\$0	28,98	1	D	

## **Explanation of Responses:**

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 12, 2023.

## Remarks:

/s/ Alex Nemiroff, as Attorneyin-Fact

06/14/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.